3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
Public ClinicalTrials.gov record NCT00275444. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-experienced Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A dose defining study of the protease inhibitor tipranavir (TPV), boosted with low dose ritonavir (RTV). Three dose combinations of TPV/RTV are administered to multiple antiretroviral experienced patients and the dose that achieves the best efficacy and safety as determined by evaluation of 2, 8, and 24-week virologic response and adverse event and laboratory profile measures would be selected for further clinical study.
Study identification
- NCT ID
- NCT00275444
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 216 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2002 (Actual)
- Primary completion
- Jan 20, 2003 (Actual)
- Completion
- Not listed
- Last update posted
- Dec 1, 2023
Started 2002
United States locations
- U.S. sites
- 38
- U.S. states
- 22
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| Boehringer Ingelheim Investigational Site | Fountain Valley | California | — | — |
| Living Hope Clinical Trials, Inc. | Long Beach | California | — | — |
| Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | — | — |
| Vincent Lombardi Cancer Center | Washington D.C. | District of Columbia | — | — |
| Therafirst Medical Center | Fort Lauderdale | Florida | — | — |
| 1501 N.W. 9th Ave | Miami | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| Boehringer Ingelheim Investigational Site | South Miami | Florida | — | — |
| Hillsborough County Health Dept. | Tampa | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Vero Beach | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| Atlanta VA Medical Center | Decatur | Georgia | — | — |
| Mercer University School of Medicine | Macon | Georgia | — | — |
| CORE Center | Chicago | Illinois | — | — |
| Rush-Presbytarian-St Luke's Medical Center | Chicago | Illinois | — | — |
| University of Louisville | Louisville | Kentucky | — | — |
| HIV Outpatient Program (H.O.P) | New Orleans | Louisiana | — | — |
| John's Hopkins University | Baltimore | Maryland | — | — |
| Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| Community Research Initiative of New England | Springfield | Massachusetts | — | — |
| University of Michigan Health System | Ann Arbor | Michigan | — | — |
| Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| Washington University | St Louis | Missouri | — | — |
| Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | — | — |
| ID Care | Hillsborough | New Jersey | — | — |
| Boehringer Ingelheim Investigational Site | Santa Fe | New Mexico | — | — |
| Albany Medical College | Albany | New York | — | — |
| University of New York at Stony Brook | Stony Brook | New York | — | — |
| Duke University Medical Center | Durham | North Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Huntersville | North Carolina | — | — |
| Wake Forest University Baptist Medical Center | Winston-Salem | North Carolina | — | — |
| Ohio State University Medical Center | Columbus | Ohio | — | — |
| Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| Boehringer Ingelheim Investigational Site | Columbia | South Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| Boehringer Ingelheim Investigational Site | Annandale | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00275444, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 1, 2023 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00275444 live on ClinicalTrials.gov.